Hepatitis B Clinical Trial
Official title:
Intradermal Hepatitis B Vaccination With Imiquimod in Occult Hepatitis B Infection
Verified date | October 2019 |
Source | The University of Hong Kong |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
During the course of chronic hepatitis B infection, patients may undergo hepatitis B surface
antigen (HBsAg) seroclearance, resulting in undetectable circulating HBsAg. With the advance
of sensitive nucleic acid detection techniques, HBsAg-negative subjects with detectable HBV
DNA in sera or liver tissues can be identified. Patients who have undetectable HBsAg and yet
detectable HBV DNA in sera or liver tissues are defined as having occult HBV infection (OBI).
OBI as a cause of liver disease in HBsAg-negative patients remains clinically important
[1,2]. Studies conducted by our research group had demonstrated that patients with HBsAg
seroclearance could still develop flare of hepatitis B, advanced liver diseases and HCC
[3-6]. Prevention of these complications in OBI patients by conventional intramuscular
hepatitis B vaccination (HBVv) remains elusive with poor amnestic anti-HBs response [7].
The objective of this prospective double-blind randomized controlled trial is to evaluate the
effect and safety of topical treatment with imiquimod immediately before intradermal
vaccination with Sci-B-Vac™ in patients with OBI. Our a priori hypothesis is that imiquimod
pretreatment would improve immune responses to Sci-B-Vac™ further in OBI patients, resulting
in HBsAb conversion. Thereby preventing subsequent complications including flare of
hepatitis, cirrhosis and HCC in these patients.
Status | Completed |
Enrollment | 120 |
Est. completion date | July 31, 2019 |
Est. primary completion date | March 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 27 Years and older |
Eligibility |
Inclusion Criteria: - Subjects recruited have to be aged =27 years (born before the universal hepatitis B immunization program for newborns introduced in Hong Kong in 1988), with documentation of loss of HBsAg without anti-HBs production during follow-up of the chronic hepatitis B infection in our clinics in Queen Mary Hospital. These patients should have normal liver function tests. - Subjects have to give written informed consent. - Subjects must be available to complete the study and comply with study procedures. - Subjects are willing to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response. Exclusion Criteria: - Subjects with a history or any illness that might interfere with the results of the study or participation in the study may pose additional risk to the subjects. - Subjects have a recent history (documented, confirmed or suspected) of a flu-like disease within a week of vaccination. - Subjects have a known allergy to components of the study vaccine Sci-B-Vac™. - Subjects have a positive urine or serum pregnancy test within 24 hours prior to vaccination, or women who are breastfeeding. - Subjects have an active neoplastic disease or a history of any hematologic malignancy. - Subjects have known chronic active hepatitis C (anti-HCV+ve), autoimmune hepatitis or cirrhosis. - Subjects have known active human immunodeficiency virus infection (anti-HIV+ve). - Subjects have known chronic liver disease due to primary biliary cirrhosis, metabolic or hereditary causes. - Subjects have received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study. - Subjects participate in another clinical study during the current study. - Subjects have axillary temperature =38°C or oral temperature =38.5°C within 3 days of intended study vaccination - Subjects have a history of alcohol or drug abuse in the last 5 years. - Subjects have any condition that the investigator believes may interfere with successful completion of the study. |
Country | Name | City | State |
---|---|---|---|
Hong Kong | University of Hong Kong | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Seroprotection rate to HBV at 12 month | Percentage of recruited subjects with anti-HBs antibody titre >10mIU/mL | 12 month | |
Secondary | Seroprotection rate to HBV at 1 month | Percentage of recruited subjects with anti-HBs antibody titre >10mIU/mL | 1 month | |
Secondary | Seroprotection rate to HBV at 6 month | Percentage of recruited subjects with anti-HBs antibody titre >10mIU/mL | 6 month | |
Secondary | GMT of anti-HBs at 1 month | Geometric mean titre of anti-HBs antibody at 1 month after vaccination | 1 month | |
Secondary | GMT of anti-HBs at 6 month | Geometric mean titre of anti-HBs antibody at 6 month after vaccination | 6 month | |
Secondary | GMT of anti-HBs at 12 month | Geometric mean titre of anti-HBs antibody at 12 month after vaccination | 12 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01182311 -
Duration of Long-term Immunity After Hepatitis B Virus Immunization
|
||
Completed |
NCT04971928 -
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
|
Phase 1 | |
Completed |
NCT03285620 -
A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
|
Phase 1 | |
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05404919 -
Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
|
Phase 2 | |
Completed |
NCT02153320 -
Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
Completed |
NCT03567382 -
Arresting Vertical Transmission of Hepatitis B Virus
|
Phase 4 | |
Not yet recruiting |
NCT04056728 -
A Phase IV Study to Assess the Safety of EupentaTM Inj
|
Phase 4 | |
Not yet recruiting |
NCT03604016 -
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
|
Phase 4 | |
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Terminated |
NCT02604199 -
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
|
Phase 2 | |
Completed |
NCT02540538 -
Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
|
Phase 1 | |
Completed |
NCT02421666 -
A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV
|
N/A | |
Completed |
NCT02169674 -
Hepatitis B Booster Study in Adolescence
|
Phase 4 | |
Completed |
NCT01917357 -
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
|
Phase 3 | |
Completed |
NCT01732354 -
Study for Consolidation Period of Chronic Hepatitis B
|
||
Completed |
NCT01368497 -
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 3 | |
Recruiting |
NCT01462981 -
Cohort of Hepatitis B Research of Amsterdam
|
N/A |